- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02194283
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers
July 22, 2014 updated by: Boehringer Ingelheim
A Double-blind (at Each Dose Level), Randomised, Placebo Controlled Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges (Dosage: 20, 40, 80 mg Three Times Daily) Over 4 Days in Healthy Male Volunteers
The main objectives of the present study are to determine pharmacokinetics of ambroxol in healthy male volunteers following repeated administration of lozenges of 20 mg ambroxol for four days
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs, 12-lead Electrocardiogram (ECG), clinical laboratory tests
- Age ≥21 and Age ≤50 year
- BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion Criteria:
- Any finding of the medical examination (including vital signs and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Actual smoker
- Alcohol abuse (more than 40 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of trial site
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
|
EXPERIMENTAL: Ambroxol - in single rising doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum measured concentration of the analyte in plasma)
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours)
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Ae0-24 (amount of the analyte that is eliminated in urine from the time point 0 until time point 24)
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
CLR,0-24 (renal clearance of the analyte determined from the time point 0 until time point 24) using AUC0-24 and Ae0-24
Time Frame: up to 24 hours after drug administration
|
up to 24 hours after drug administration
|
Cmax,ss (maximum concentration of the analyte in plasma at steady state)
Time Frame: up to 120 hours after first drug administration
|
up to 120 hours after first drug administration
|
tmax,ss (time from last dosing to maximum concentration at steady state)
Time Frame: up to 120 hours after first drug administration
|
up to 120 hours after first drug administration
|
Cmin,ss (minimum concentration of the analyte in plasma at steady state)
Time Frame: up to 120 hours after first drug administration
|
up to 120 hours after first drug administration
|
AUC72-96,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform 24 hour interval matching Day 1)
Time Frame: up to 96 hours after first drug administration
|
up to 96 hours after first drug administration
|
Ae72-96,ss (amount of analyte that is eliminated in urine at steady state from the time point 72 to time point 96)
Time Frame: up to 96 hours after first drug administration
|
up to 96 hours after first drug administration
|
CLR,72-96,ss (renal clearance of the analyte in plasma from the time point 72 until the time point 96 at steady state) using AUC72-96 and Ae72-96
Time Frame: up to 96 hours after first drug administration
|
up to 96 hours after first drug administration
|
λz,ss (terminal rate constant in plasma at steady state)
Time Frame: up to 120 hours after first drug administration
|
up to 120 hours after first drug administration
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Time Frame: up to 120 hours after first drug administration
|
up to 120 hours after first drug administration
|
RA (accumulation ratio)
Time Frame: up to 96 hours after first drug administration
|
up to 96 hours after first drug administration
|
LI (linearity index)
Time Frame: up to 96 hours after first drug administration
|
up to 96 hours after first drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events
Time Frame: up to 36 days
|
up to 36 days
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: up to 36 days
|
up to 36 days
|
Number of patients with clinically significant changes in vital signs (blood pressure [BP], pulse rate [PR])
Time Frame: up to 36 days
|
up to 36 days
|
Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)
Time Frame: up to 36 days
|
up to 36 days
|
Assessment of tolerability on a 4-point scale
Time Frame: 10 days after last drug administration
|
10 days after last drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (ACTUAL)
November 1, 2009
Study Registration Dates
First Submitted
July 17, 2014
First Submitted That Met QC Criteria
July 17, 2014
First Posted (ESTIMATE)
July 18, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 23, 2014
Last Update Submitted That Met QC Criteria
July 22, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18.493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States